Eales disease (ED) is a common, idiopathic, inflammatory retinal vasculitis that particularly affects young adults. Current treatments available for ED include corticosteroids, laser photocoagulation, retinal cryotherapy, and surgery, but a recent study found that using intravitreal bevacizumab injections may produce better outcomes and reduce the need for surgery.
Eales disease (ED) is a common, idiopathic, inflammatory retinal vasculitis that particularly affects young adults. The pathogenesis of ED is poorly understood, but some studies have attributed the disease to a response to Mycobacterium Tuberculosis antigens. The disease involves stages of retinal vasculitis, nonperfusion, neovascularization, vitreous hemorrhage (VH) and tractional retinal detachment (TRD).
Current treatments available for ED include corticosteroids, laser photocoagulation, retinal cryotherapy, and surgery, but a recent study, published in the Pakistan Journal of Medical Sciences, found that using intravitreal bevacizumab injections to treat ED may produce better outcomes and reduce the need for surgery.
The paper reports on a trial carried out at a single center from May 2015 to December 2016 in 26 patients—and 52 eyes—diagnosed with ED. Patients were randomized to receive either intravitreal bevacizumab injections or standard treatment with steroids and photocoagulation.
In the group that received bevacizumab, 9 eyes (24.6%) progressed to stage III or stage IV disease, while in the standard treatment group, 18 eyes (69.2%) progressed in disease severity. Six eyes in the bevacizumab group and 16 in the standard treatment group required surgery.
The groups showed comparable regression of vasculitis, but regression of neovascularization was observed more in the bevacizumab group (16 eyes) than the standard treatment group (6 eyes).
The difference in both groups in terms of final disease stage at 12 weeks was not statically significant (P = .066), though the number of eyes in stage I was 15 (58%) in the bevacizumab group versus 6 (23%) in the standard treatment group. “This shows considerably more number of eyes showing regression of ED,” write the authors.
The authors conclude that giving intravitreal bevacizumab injections monthly in patients with stage I or stage II ED results in more regression in vascularization and less need for surgery versus standard therapy, and it should be considered as an adjunct therapy to avoid progression of the disease.
Reference
Mehboob MA, Tahir M, Batool H. Role of intravitreal bevacizumab in management of Eale’s disease. Pak J Med Sci. 2018;34(2):333-337. doi: 10.12669/pjms.342.14483.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.